GLP-1 heavyweights Eli Lilly and Novo Nordisk are trading haymakers as they scale up production to meet the overwhelming demand for their revolutionary obesity drugs.
A month after Lilly revealed a $5.3 billion investment to increase its manufacturing capacity, Novo has answered.
